SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bacil Pharma informs about newspaper clipping

17 May 2023 Evaluate

Bacil Pharma has informed that it enclosed newspaper clipping for Audited Financial Results as per Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 for the Year and Quarter ended 31st March, 2023 published in ‘Pratahkal’ (Marathi) and ‘Financial Express’ (English)on 17th May, 2023 for the records.

The above information is a part of company’s filings submitted to BSE.

Bacil Pharma Share Price

54.01 -0.36 (-0.66%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×